Everolimus (RAD001) 化学構造
分子量: 958.22

高品質保証

文献中の引用(49)

カスタマーフィードバック(5)

Quality Control & MSDS

製品説明

  • Compare mTOR Inhibitors
    mTOR製品生物活性の比較
  • 研究分野
  • Combination Therapy
    併用療法

製品の説明

生物活性

製品説明 Everolimus (RAD001) は、1.6-2.4nMのIC50によるFKBP12のmTOR阻害剤です。
ターゲット mTOR (FKBP12)
IC50 1.6-2.4 nM [1]
In vitro試験 Everolimus exhibits the immunosuppressive activity which is comparable to that of rapamycin. Everolimus competes with immobilized FK 506 for binding to biotinylated FKBP12 and shows the inhibitory effect on a two-way MLR performed with spleen cells from BALB/c and CBA mice with IC50 of 0.12-1.8 nM. [1] Everolimus also shows antiangiogenic/vascular effects in VEGF-induced HUVEC proliferation with IC50 of 0.12 nM and bFGF-induced HUVEC proliferation with IC50 of 0.8 nM, respectively. [2] A recent study shows that Everolimus shows a dose-dependent inhibitory effects on both the total cells and the stem cells from the BT474 cell line and the primary breast cancer cells with IC50 of 156 nM in total cells of primary breast cancer cells and 71 nM in total cells of BT474 cells. In addition, combination treatment with Everolimus and trastuzumab produces the significantly increased inhibition on the growth of cancer stem cells with the inhibition rate increased by more than 50 %. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
SQ20B NUS5fVNWS3m2b4TvfIlkKEG|c3H5 NF\uS2I4OiCq MVzEUXNQ MmnuTWM2OD13LkWg{txO MUOyOFQ1PTNzMR?=
Colo205 Ml3zR5l1d3SxeHnjJGF{e2G7 NWrPS3diPzJiaB?= NV30U5lbTE2VTx?= NWjHbFNjUUN3ME2yNEDPxE1? NWHRW292OjR2NEWzNVE>
ColoR NGTFPI5EgXSxdH;4bYMhSXO|YYm= NUnneWVHPzJiaB?= MorZSG1UVw>? M{fCTGlEPTB;OD63JO69VQ>? M1fkdVI1PDR3M{Gx
HCT116 NUnqO2s1S3m2b4TvfIlkKEG|c3H5 Mnu5O|IhcA>? M2Dlc2ROW09? MVXJR|UxRTF{IN88US=> MkWwNlQ1PDV|MUG=
HT29 MlLKR5l1d3SxeHnjJGF{e2G7 M1WxdVczKGh? MoHySG1UVw>? MWjJR|UxRTF3IN88US=> NHHjclkzPDR2NUOxNS=>
CAKI1 MX;DfZRwfG:6aXOgRZN{[Xl? NIHET3o4OiCq Mn3QSG1UVw>? MmTSTWM2OD1zNDFOwG0> M2HsblI1PDR3M{Gx
SK-HEP1 MXfDfZRwfG:6aXOgRZN{[Xl? MV:3NkBp NULlPY1jTE2VTx?= MXzJR|UxRTF{IN88US=> Mlq3NlQ1PDV|MUG=
DU145 NEToUnpEgXSxdH;4bYMhSXO|YYm= M3zhe|czKGh? MUTEUXNQ MVPJR|UxRThizszN MorzNlQ1PDV|MUG=
OVCAR3 MVTDfZRwfG:6aXOgRZN{[Xl? M2fIWFczKGh? MV7EUXNQ NX;YOJR3UUN3ME2xOkDPxE1? NHjxXIYzPDR2NUOxNS=>
HOP62 M{fMV2N6fG:2b4jpZ{BCe3OjeR?= NF6zW4c4OiCq NUTHSINjTE2VTx?= NXezZ3RnUUN3ME2xPUDPxE1? MYqyOFQ1PTNzMR?=
Colo205 MVPGeY5kfGmxbjDBd5NigQ>? MWWyOEBp M{nTfmROW09? MYDJcohq[mm2czDtWG9TSzFiaX6gbJVu[W5iQ1;MU|IxPSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gV|YheGixc4Doc5J6dGG2aX;uJIF1KDBwMTD0c{A5KHWP NGL6TZgzPDh|NkC3NC=>
Colo205 MVHGeY5kfGmxbjDBd5NigQ>? MV2yOEBp NWTXellFTE2VTx?= NVfpdINGUW6qaXLpeJMhdVSRUlOxJIlvKGi3bXHuJGNQVE9{MEWgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKDRvRVLQNUBxcG:|cHjvdplt[XSrb36gZZQhOC5zIITvJFghfU1? NHXseI0zPDh|NkC3NC=>
SK-HEP1 NFH5TVBHfW6ldHnvckBCe3OjeR?= NG\QOXYzPCCq Mlz0SG1UVw>? MnPCTY5pcWKrdIOgcXRQWkNzIHnuJIh2dWGwIGPLMWhGWDFiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIH;mJHM3KHCqb4PwbI9zgWyjdHnvckBifCByLkGgeI8hQCC3TR?= MYqyOFg{PjB5MB?=
SK-HEP1 NHrtRXBHfW6ldHnvckBCe3OjeR?= MVmyOEBp NETUe2FFVVOR MnLyTY5pcWKrdIOgcXRQWkNzIHnuJIh2dWGwIGPLMWhGWDFiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIH;mJFQuTUKSMTDwbI9{eGixconsZZRqd25iYYSgNE4yKHSxIEigeW0> NGm4dmYzPDh|NkC3NC=>

... Click to View More Cell Line Experimental Data

In vivo試験 Everolimus (0.1 to 10 mg/kg) dose-dependently inhibits growth of the primary (ear) and lymph node metastases of B16/BL6 melanoma, with decreased total number of vessels and reduced mature vessels. [2] In a xenograft animal model of BT474 stem cells, Everolimus shows significant reductions in mean tumor sizes (590.6 mm3), compared to the control group with a tumor size of 698 mm3. Furthermore, combination treatment with Everolimus and trastuzumab significantly decreases the xenograft tumor size (410.8 mm3) more than Everolimus treatment alone. [3]
臨床試験 Everolimus is currently in Phase I clinical trials in patients with Unspecified Adult Solid Tumor.
特集

プロトコル (参考用のみ)

キナーゼアッセイ: [1]

FKBP12 binding assay & Mixed lymphocyte reaction (MLR) FKBP12 binding assay: Binding to the FK 506 binding protein (FKBP12) is indirectly assessed by means of an ELISA-type competition assay. FK 506 is included in each individual experiment as a standard, and the inhibitory activity is expressed as relative IC50 compared to FK 506 (rIC50 = IC50 Everolimus/IC50 FK 506). Mixed lymphocyte reaction (MLR): The immunosuppressive activities of RAP and its derivatives are assessed in a two-way MLR, using spleen cells of BALB/c and CBA mice. RAP is included in each individual experiment as a standard, and the inhibitory activity is expressed as relative IC50 compared to RAP (rIC50 = IC50 Everolimus/IC50 RAP).

細胞アッセイ: [3]

細胞株 BT474 cell line and the primary breast cancer cells
濃度 0.001-10 μM
反応時間 24 hours
実験の流れ The 3-(4-5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide dye reduction assay (MTT assay) is used to compare the effects of Everolimus or trastuzumab on total breast cancer cells and breast CSCs. The total cells and the stem cells from the BT474 cell line and the primary breast cancer cells are respectively seeded into 96-well plates with different concentrations of the drugs, with five wells for each concentration, and the cells are cultured at 37 °C with 5 % CO2 in an incubator for 24 hours. The concentrations of Everolimus are 1 nM, 10 nM, 100 nM, 1 μM and 10 μM, and the concentrations of trastuzumab are 0.5 μg/mL, 1 μg/mL, 10 μg/mL, 50 μg/mL, and 100 μg/mL. The combinatorial inhibitory effect of Everolimus and Trastuzumab on the in vitro growth of breast CSCs is examined by MTT assay as well using 10 μg/mL trastuzumab in combination of increasing concentrations of everolimus (1 nM, 10 nM, 100 nM and 1 μM). After drug treatment for 24 hours, 20 μL MTT [5 mg/mL in phosphate buffered saline (PBS)] is added to each well, and the cells are incubated at 37 °C with 5 % CO2 and saturated humidity for 4 hours. Following the subsequent removal of the supernatant, 150 μL dimethyl sulfoxide (DMSO) is added to each well, and the cells are vortexed for 10 minutes. The light absorbance (OD value) is measured for each well using an ELISA reader. Each experiment is repeated in triplicate, and dose–response curves are plotted. The probit software of the statistical software package SPSS 17.0 for Windows is used to calculate the inhibitory concentration (IC50) of Everolimus.

動物実験: [3]

動物モデル Cultured BT474 stem cells are injected beneath the left breast pad of BALB/c nude mice.
製剤 Everolimus is dissolved in saline.
投薬量 ≤2 mg/kg
投与方法 Administered via p.o.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download Everolimus (RAD001) SDF
分子量 958.22
化学式

C53H83NO14

CAS No. 159351-69-6
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 30 mg/mL (31.3 mM)
エタノール 7 mg/mL (7.3 mM)
<1 mg/mL (<1 mM)
In vivo 30% Propylene glycol (dissolve first)+5% Tween 80+ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine, rapamycin deriv

文献中の引用 (49)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related mTOR 阻害剤

  • MHY1485

    MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.

  • CHIR-99021 (CT99021)

    CHIR-99021(CT99021)は、GSK-3αとGSK-3β阻害剤で、IC50 がそれぞれ 10 nM と 6.7 nMである。

  • Dorsomorphin

  • Afuresertib (GSK2110183)

    Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

  • Rapamycin (Sirolimus)

    Rapamycin (Sirolimus) は、特定のmTOR阻害剤で、IC50 が ~0.1 nMです。

  • AZD8055

    AZD8055は、0.8nMのIC50によるmTORの新しいATP競争的阻害剤です。

    Features:First drug to inhibit both types of mTOR protein.

  • Torin 1

    Torin1は、mTORの強力な阻害剤で、IC50 が 2-10 nMです。

  • Temsirolimus (CCI-779, NSC 683864)

    Temsirolimus (CCI-779, NSC 683864)は、特定のmTOR阻害剤で、IC50 が 1.76 μM。

  • INK 128 (MLN0128)

    INK 128 (MLN0128)は、有力で選択的なmTOR 阻害剤で、 IC50 が 1 nMです。

最近チェックしたアイテム

Tags: Everolimus (RAD001)を買う | Everolimus (RAD001)供給者 | Everolimus (RAD001)を購入する | Everolimus (RAD001)費用 | Everolimus (RAD001)生産者 | オーダーEverolimus (RAD001) | Everolimus (RAD001)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ